CD4 and acute myeloid leukemia: To investigate differences in T-cell polyfunctionality, we investigated the secreted proteome of activated bead-sorted CD4 and CD8 T cells using the IsoPlexis 32-plex human adaptive immune panel from 21 patients with RelRef AML enrolled in a phase II clinical trial using combination Aza/Nivo therapy [10 patients were responders and 11 patients were nonresponders (NR)] (Fig. 1A).